WEBINAR—Creating New Horizons in Heart Failure Treatment

June 23, 2022
11 a.m. EDT

Watch the on-demand webinar

Heart failure is a devastating disease that causes significant morbidity and mortality and accounts for 1 in 9 deaths in the U.S. There is a strong impetus to develop alternative treatment strategies because therapeutic options for severe heart failure are limited to organ transplantation and left ventricular assist device. Heartseed Inc., a Tokyo-based biotechnology company, is developing a first-in-class cell-therapy called “remuscularization.” Remuscularization aims to replace injured or nonviable cardiac muscle (myocardium) with fresh muscle cells (cardiomyocytes).

Heartseed has developed technology to produce large number of purified ventricular cardiomyocytes from induced pluripotent stem cells (iPS) cells to form spheroids and to transplant into myocardium efficiently. Heartseed Chief Medical Officer and Head of Research and Development Takehiko Kaneko, MD, will explain remuscularization and Heartseed’s technology of iPS cell production, purification and transplantation.

Speaker

Takehiko Kaneko, MD, is chief medical officer and head of research and development of Heartseed Inc. in Tokyo. Prior to joining Heartseed, Kaneko served on the leadership team at Tokyo-based SanBio Co. Ltd., where he was responsible for development and regulatory of cell therapy products. Kaneko has also worked in medical affairs at Bristol-Myers Squibb, clinical development at Pfizer and early development at Novartis. He received his medical degree from Keio University School of Medicine in Japan.